Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [QUIET] · [BUSINESS]
2 clusters · 4 sources · 14 days · First seen · Last updated
GLP-1 drug market and patent evolution
Overview
The pharmaceutical landscape for GLP-1 drugs is undergoing significant shifts, particularly regarding patenting and market expansion. Global patent applications for these drugs have increased by 146% over the last five years as companies attempt to extend product lifecycles through secondary patents on delivery devices, oral formulations, and new synthesis processes.
In India, the upcoming March 2026 patent expiry for semaglutide has prompted a massive rollout of over fifty generic brands from companies such as Sun, Dr. Reddy’s, Zydus, and Alkem. This rapid generic introduction has underscored a reliance on imported peptide ingredients and European-made auto-injector devices.
As the market evolves, companies are looking toward secondary clinical benefits and side-effect management. Bayer, for instance, is evaluating the development of products in digestive health, nutrition, and supplements to mitigate side effects like nausea and muscle mass loss associated with GLP-1 obesity treatments. This aligns with Bayer’s strategic goal to triple its consumer health business in India by 2030.
Entities
Biocon · Novo Nordisk · Julio Triana · Bayer · Dr. Reddy’s Laboratories
Timeline
-
[BUSINESS] 2 sourcesBayer evaluates products to mitigate GLP-1 side effects
Bayer is exploring consumer health products, such as digestive aids and supplements, to address side effects of GLP-1 obesity medications as part of its expansion strategy in India.
-
[BUSINESS] 2 sourcesGLP-1 drug patent applications surge amid semaglutide patent expiry
GLP-1 patent applications have risen 146% in five years, driven by efforts to extend product lifecycles. India faces a pivotal opportunity to move from generic semaglutide production to complex molecule mastery
Sources
chemindigest.com · diariodesalud.com.do · empresaexterior.com · manufacturingchemist.com